3,302
Views
10
CrossRef citations to date
0
Altmetric
Otoneurology

Intratympanically administered steroid for progressive sensorineural hearing loss in Ménière’s disease

, , &
Pages 982-986 | Received 17 Jun 2019, Accepted 08 Aug 2019, Published online: 09 Sep 2019

References

  • Harcourt J, Barraclough K, Bronstein AM. Meniere's disease. BMJ. 2014;349:g6544. doi:10.1136/bmj.g6544
  • Oberman BS, Patel VA, Cureoglu S, et al. The aetiopathologies of Ménière's disease: a contemporary review. Acta Otorhinolaryngol Ital. 2017;37:250–263.
  • Alexander TH, Harris JP. Current epidemiology of Meniere's syndrome. Otolaryngol Clin North Am. 2010;43:965–970.
  • Molnár A, Maihoub S, Tamás L, et al. Possible effect of diabetes and hypertension on the quality of life of patients suffering from Ménière's disease. Orv Hetil. 2019;160:144–150.
  • Havia M, Kentala E. Progression of symptoms of dizziness in Ménière's disease. Arch Otolaryngol Head Neck Surg. 2004;130:431–435.
  • Mateijsen DJ, Van Hengel PW, Van Huffelen WM, et al. Pure-tone and speech audiometry in patients with Menière's disease. Clin Otolaryngol Allied Sci. 2001;26:379–387.
  • McNeill C, Freeman SR, McMahon C. Short-term hearing fluctuation in Meniere's disease. Int J Audiol. 2009;48:594–600.
  • Schuknecht HF. Meniere's disease: a correlation of symptomatology and pathology. Laryngoscope. 1963;73:651–665.
  • Stachler RJ, Chandrasekhar SS, Archer SM, et al. Clinical practice guideline: Sudden hearing loss. Otolaryngol Head Neck Surg. 2012;146:S1–S35.
  • Memari F, Hassannia F. Effect of intratympanic dexamethasone on controlling tinnitus and hearing loss in Meniere’s disease. Iran J Otorhinolaryngol. 2014;26:129–133.
  • Filipo R, Covelli E, Balsamo G, et al. Intratympanic prednisolone therapy for sudden sensorineural hearing loss: A new protocol. Acta Otolaryngol. 2010;130:1209–1213.
  • Dispenza F, Amodio E, De Stefano A, et al. Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study. Eur Arch Otorhinolaryngol. 2011;268:1273–1278.
  • Hoes JN, Jacobs JW, Verstappen SM, et al. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68:1833–1838.
  • Liu YC, Chi FH, Yang TH, et al. Assessment of complications due to intratympanic injections. World J Otorhinolaryngol Head Neck Surg. 2016;2:13–16.
  • Pitovski DZ, Drescher MJ, Drescher DG. Glucocorticoid receptors in the mammalian inner ear: RU 28362 binding sites. Hear Res. 1994;77:216–220.
  • Alexiou C, Arnold W, Fauser C, et al. Sudden Sensorineural Hearing loss: does application of glucocorticoids make sense? Arch Otolaryngol Head Neck Surg. 2001;127:253–258.
  • Nevoux J, Barbara M, Dornhoffer J, et al. International consensus (ICON) on treatment of Ménière’s Disease. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135:29–32.
  • Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, et al. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière’s disease: A two-year prospective, placebocontrolled, double-blind, randomized trial. Otolaryngol Head Neck Surg. 2005;133:285–294.
  • Herraiz C, Plaza G, Aparicio JM, et al. Transtympanic Steroids for Ménière’s Disease. Otol Neurotol. 2010;31:162–167.